SFEE Highlights Significant Delays in Greek Patient Access to New Medicines
The Association of Pharmaceutical Companies of Greece (SFEE) has raised alarms regarding substantial delays in bringing new, innovative medicines to Greek patients, with access often occurring nearly two years after European Medicines Agency (EMA) approval. This situation poses significant challenges for patient care and the pharmaceutical market in Greece.
Executive Summary
- Greek patients wait nearly two years after EMA approval before new innovative medicines become available — a delay that places Greece among the slowest EU markets for patient access. The Pharmaletter
- Only 25% of 173 new medicines assessed are fully accessible to Greek patients; a further 18% are available only with restrictions through the Electronic Prescription System. The Pharmaletter
- Pharmaceutical companies increasingly signal they do not intend to launch new products in Greece, raising concerns about long-term market viability and R&D prioritization for the country. The Pharmaletter
- The Greek Health Ministry has proposed an innovation fund for orphan drugs as a potential pathway to improve access for rare-disease patients. PubMed Central
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
SFEE Flags Major Delays in Greek Patient Access to New Medicines
The Association of Pharmaceutical Companies of Greece (SFEE) has raised alarms regarding substantial delays in bringing new, innovative medicines to Greek patients, with access often occurring nearly two years after European Medicines Agency (EMA) approval. This situation poses significant challenges for patient care and the pharmaceutical market in Greece. For BD teams and investors modeling European launches, the Greek access gap is becoming a material factor in market-prioritization decisions. The Pharmaletter
Key Takeaways
- Greek patients wait nearly two years after EMA approval before new innovative medicines become available — a delay that places Greece among the slowest EU markets for patient access. The Pharmaletter
- Only 25% of 173 new medicines assessed are fully accessible to Greek patients; a further 18% are available only with restrictions through the Electronic Prescription System. The Pharmaletter
- Pharmaceutical companies increasingly signal they do not intend to launch new products in Greece, raising concerns about long-term market viability and R&D prioritization for the country. The Pharmaletter
- The Greek Health Ministry has proposed an innovation fund for orphan drugs as a potential pathway to improve access for rare-disease patients. PubMed Central
How Severe Is the Access Gap for Greek Patients?
The SFEE presented findings from two studies at a press conference in June 2026, quantifying a problem that clinicians and patient groups have flagged for years. Of 173 new medicines reviewed, only 25% are fully accessible to Greek patients. Another 18% are available with restrictions — typically through the Electronic Prescription System — meaning nearly 57% of new innovative treatments are effectively out of reach for the majority of patients who might benefit. The Pharmaletter
The timeline compounds the severity. New innovative medicines reach Greece with a delay of almost two years from their EMA approval date. By the time a therapy clears national pricing negotiations, budget-impact assessments, and reimbursement-list inclusion, patients in Germany, France, or the Netherlands may have been receiving it for nearly 24 months. One analysis summarized the dynamic bluntly: Greeks wait almost two years for access to new treatments, while pharmaceutical companies increasingly say they do not intend to launch new products there. The Pharmaletter
The underfunding of Greece's pharmaceutical system is a root cause. SFEE's president has warned that the dire economic constraints on the health budget directly translate into delayed or denied access to new, life-saving medicines. Clawback mechanisms — which recoup excess pharmaceutical spending from manufacturers — add another layer of financial unpredictability that discourages companies from committing to the market. The Pharmaletter
Why Should Pharma BD Teams and Investors Care?
For business development teams evaluating European market entry sequences, the Greek access gap introduces a material commercial calculation. When nearly three-quarters of new innovative medicines are either unavailable or restricted, the revenue case for prioritizing a Greek launch weakens considerably. Companies must weigh whether the market's volume potential justifies the cost of navigating a system where clawback obligations and reimbursement uncertainty erode margins.
The risk is a self-reinforcing cycle. Limited launches lead to limited access, which further discourages future filings. The SFEE has criticized the R&D clawback offset scheme, arguing it penalizes companies that do invest in the Greek market. When manufacturers cannot predict whether a product will achieve meaningful patient access — or whether they will face retrospective financial penalties — the incentive to file diminishes. Some companies have already signaled they do not plan to launch certain new products in Greece at all. The Pharmaletter
For investors modeling European revenue forecasts, Greece may increasingly need to be treated as a delayed or de-prioritized market relative to larger EU economies where pricing and reimbursement pathways are more predictable. Analysts should watch for signals that major originator companies are deprioritizing Greek filings — a trend that would further widen the access gap and could trigger downgrades in long-term market-size estimates for the country.
What Policy Changes Are on the Horizon?
The EMA remains the gateway for initial marketing authorization across the EU, but national-level pricing and reimbursement decisions determine when — or whether — patients actually receive approved therapies. In Greece, the lag between EMA approval and patient availability stems from protracted negotiations over pricing, budget-impact assessments, and the structure of reimbursement lists. EMA
There are signs of policy movement. The Greek Health Ministry has proposed designing parallel funding for orphan drugs in the form of an innovation fund, intended to better ensure patients' access to treatments for rare diseases. This proposal, documented in a 2025 analysis of Greek rare disease policy published in PubMed Central, represents one of the more concrete governmental acknowledgments that the current funding model is failing to deliver timely access for high-need patient populations. PubMed Central
However, patient groups have warned that recent extensions to drug reimbursement rules could introduce additional criteria that slow access further, even as the government signals openness to reform. The tension between fiscal containment and timely patient access remains the central policy challenge. The SFEE has acknowledged some positive responses from the government but stresses that structural reform — not incremental adjustments — is needed to close the gap. The Pharmaletter
Frequently Asked Questions
What are the primary concerns raised by SFEE regarding new medicines in Greece?
SFEE is concerned about significant delays — nearly two years post-EMA approval — in Greek patients' access to new innovative medicines. The association's research found that only 25% of 173 new medicines assessed are fully accessible, with another 18% available only under restrictions. The Pharmaletter
Who is most affected by these access delays in Greece?
Greek patients bear the direct burden, particularly those with rare diseases or conditions requiring innovative therapies that are available elsewhere in the EU. Pharmaceutical companies face market-access uncertainty and may deprioritize or skip Greek launches entirely, which further reduces the treatment pipeline available to patients. The Pharmaletter
What regulatory steps could improve the situation?
The Greek Health Ministry has proposed an innovation fund for orphan drugs as a parallel funding mechanism to improve rare-disease patient access. Broader reforms to the clawback system and faster pricing and reimbursement negotiations would also be needed to meaningfully close the access gap. PubMed Central
How does Greece compare to other EU markets on drug-access timelines?
Greece is among the slowest EU markets, with a delay of almost two years from EMA approval to patient availability. Most larger EU markets — including Germany and France — achieve patient access within months of EMA authorization, making Greece a significant outlier in the European access landscape. The Pharmaletter
What should pharma companies and investors watch for next?
Key signals include whether the Greek government moves forward with the proposed orphan-drug innovation fund, any revisions to the clawback framework, and whether major originator companies publicly deprioritize Greek market entries. Each of these would serve as a catalyst — positive or negative — for the country's commercial attractiveness. The Pharmaletter
Related coverage
This article follows our editorial standards. Report a correction via editorial contact.
